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almost three years after publication of the “carotid revas-
cularization endarterectomy versus stent trial” (CREST) main
results?1 Was CREST a bad trial? Without hesitation, the
answer should be “No”. CREST was designed in the late
1990s and started in 2000.2 At the time, there had been no
adequate randomized comparison of carotid endarterec-
tomy (CEA) and protected carotid angioplasty (CAS). The
reason for CREST was self-evident: compare protected CAS
and CEA in low-surgical-risk but symptomatic patients. It
was the ﬁrst trial implementing a lead-in-phase to guide
interventionalist experience. CREST added substantially to
the body of data comparing CEA with CAS, with the lowest
death/stroke rates ever achieved in a randomized trial on
carotid revascularization independent of indicative symp-
toms and type of intervention. So far so good, but where
did it go wrong?
CREST was set-up to randomize symptomatic patients,
but inclusion of asymptomatics was necessary to maintain
enrollment. Although this is not a ﬂaw per se, publicity of
main results uncritically on differentiation between
asymptomatics and symptomatic patients is a serious
FLAW! CREST data were initially presented as showing that
there were no differences in outcomes between the two
procedures.3 The primary endpoint which included death
stroke and myocardial infarction (MI) within 30 days was
4.5% for CEA and 5.2% for stenting (NS), leading the in-
terventionists to claim equivalence of the two procedures.
Subsequent “subgroup” analyses showed that CAS was
associated with higher stroke and death rates in symp-
tomatic patients, females, and patients >65 years.
By that time, the general public opinion already had been
inﬂuenced and molded, and CREST and subsequent guide-
lines were used to “promote wider use of CAS in standard
and low risk symptomatic patients”. Headlines in national
newspapers concluded that “CAS and CEA were equally as
safe and effective in terms of stroke prevention”.4,5 This
statement was factually incorrect because CREST, as in all
trials on CAS versus CEA, showed that CAS was associated
with a signiﬁcantly higher risk (almost twofold excess) of
procedural stroke. Uncritical interpretation of the CREST
data (and initially incompletely reported data) could fatallyDOI of original article: http://dx.doi.org/10.1016/j.ejvs.2013.02.011
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reader should especially consider what CREST (and the
other trials) did NOT tell you.6
The American Heart Association (AHA) guidelines un-
doubtedly are the cornerstone for practice worldwide. Not
including any reference to ICSS (still the largest-ever ran-
domized trial in symptomatic patients comparing CEA with
CAS) in the 2011 AHA guidelines received ﬁerce criticism.7
Furie wrongly suggested that data were not available to
the review group at that time.8 In reality, ICSS data were
released (both on conference and ahead of print) before
CREST!9 The complete omission of the ICSS trial by the AHA
is still inexplicable. Several months later, in a revised version
of the guidelines, ICSS was included, but despite this, the
recommendations were identical to the ﬁrst AHA guide-
lines!10 This uncritical and unbalanced positioning in se-
lective data implementation did harm to the international
credibility of the AHA. Notwithstanding the overall re-
sponsibility of the primary investigators for reporting
balanced conclusions, merely the role of editors of leading
journals, guideline committees, and international newspa-
pers, should be denounced to prevent the switch from
incomplete data reporting and misinterpretation into
deception.
CREST initially concluded that “peri-operative MI was
independently associated with increased future mortality
and remained an important consideration in choosing the
mode of carotid revascularization or medical therapy”.3 It
was long assumed that the excess mortality in patients with
procedural MI was largely attributable to deaths after CEA.
However, it turned out to be the opposite. A greater pro-
portion of late deaths was observed in CAS patients who
had suffered a periprocedural MI.11 Moreover, CREST
recently showed that stroke after carotid intervention was
independently associated with a near threefold increase in
future mortality.12 This led Wesley Moore, PI of the CREST
trial, to state that: “The thing we learned was that the
simple addition of death, stroke, and MI represents a design
error!”13 The most important priority in any carotid inter-
vention trial should be the prevention of stroke, and not to
divert attention by risk of periprocedural MI. In essence, all
primary events are important but not of equal
consequence.
In conclusion, CREST’s initial report and claims of equiv-
alence of the two therapeutic procedures in both the short
and long term were unjustiﬁed. CREST, as with any other
RCT comparing CEA with CAS, in fact showed us signiﬁcantly
higher stroke and death rate associated with CAS. Or, in the
words of Wesley Moore “It should now be apparent that
G.J. de Borst and J.-B. Ricco 547the current technique employed for carotid artery stenting
is not competitive with endarterectomy”.REFERENCES
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